Surgery News and Research

RSS

Enrollment complete in Medtronic's CoreValve U.S. Trial for severe aortic stenosis

Medtronic, Inc. today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The company also received approval from the U.S. Food and Drug Administration (FDA) for an extended investigation to continue enrolling extreme risk patients under a Continued Access Study protocol.

From Medtronic 25 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

Novel detection of ovarian cancer in early stages

Ovarian cancer is often detected at a late stage and it is the leading cause of death due to gynecological cancers, and the sixth leading cause of cancer death in women. According to latest discovery by researchers at Sydney’s Garvan Institute there may be a way this killer cancer is detected earlier.

24 Jan 2012

Latest attacks in Jonglei, South Sudan, perpetuate a pattern of extreme violence, says Médecins Sans Frontières

In the state of Jonglei in South Sudan, civilians continue to bear the brunt of inter-communal fighting. Wounded patients are still arriving at the Médecins Sans Frontières hospital in Pibor, three weeks after the violent attack on the town and outlying villages in Pibor County. Many were injured in the bush, where thousands have remained, afraid to come out of hiding. Médecins Sans Frontières medical teams are now treating serious wound infections, some several weeks old. Since re-launching emergency medical activities in Pibor on 7 January, Médecins Sans Frontières has treated 47 patients with gunshot wounds – 16 women and 8 children. A further 43 patients have so far been treated for stab wounds, beatings or wounds sustained while fleeing in the bush.

24 Jan 2012

Dutaseride may help prevent progression of early stage prostate cancer: Study

A new study suggests that men with early stage prostate cancer may benefit with drugs that can slow or stop the cancer’s progress. Less than 10 percent of the 100,000 men each year who are diagnosed with early-stage prostate cancer and have the option of leaving the cancer in place. Rest get it removed using surgery or radiation. But those treatments can have serious side effects like impotence and incontinence.

24 Jan 2012

Stem cells show promise in treating blindness

A medical breakthrough was reported Monday in the journal The Lancet wherein the results of a therapy using human embryonic stem cells in two legally blind patients was described.

24 Jan 2012

Study reports Tennessee collaborative improves quality of surgical care

A new study published online today in the Journal of the American College of Surgeons finds hospitals participating in a regional collaborative of the American College of Surgeon's National Surgical Quality Improvement Program (ACS NSQIP-), achieved substantial improvements in surgical outcomes, such as reducing the rates of acute renal failure and surgical site infections.

24 Jan 2012

UCSD receives approval to acquire NVCI

UC San Diego Health System has received approval to acquire the Nevada Cancer Institute (NVCI), the official cancer institute of the state of Nevada, as an affiliate health care provider. The expansion represents a partnership between California and Nevada in offering lifesaving cancer care to patients through expert diagnosis, novel treatments and clinical trials.

24 Jan 2012

Loyola hand surgeon restores circulation and function of thumb and index finger

Tom Thompson nearly lost his left thumb and index finger in a power saw injury, but Loyola University Medical Center hand surgeon Dr. Randy Bindra was able to restore circulation and function to the mangled digits in a delicate 5½ hour surgery.

24 Jan 2012

Covidien releases results of TurboHawk and SpiderFX combination study on P.A.D.

Covidien, a leading global provider of healthcare products, today released the results of the DEFINITIVE Ca++ study.

24 Jan 2012

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

24 Jan 2012

OPKO acquires two new prostate cancer biomarkers from Arctic Partners

OPKO Health, Inc. today announced the acquisition of an exclusive license from Arctic Partners Ab Oy for two biomarkers in the kallikrein family which, used together with prostate specific antigen (PSA), can reduce the need for prostate biopsies by over 50%.

24 Jan 2012

Dutasteride delays prostate cancer progression in men

For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network.

24 Jan 2012

FDA grants 510(k) clearance for Medtronic's Aquamantys SBS 5.0 Sheathed Bipolar Sealer

Medtronic, Inc. announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys® SBS 5.0 Sheathed Bipolar Sealer, a new addition to the spine portfolio of the company's Advanced Energy business.

From Medtronic 23 Jan 2012

FzioMed's DYNAVISC adhesion barrier gel receives European CE Mark approval

FzioMed, Inc. is pleased to announce that it has received CE Mark approval to market DYNAVISC adhesion barrier gel in Europe for tendon and peripheral nerve surgery.

23 Jan 2012

Haymarket Media launches ChemotherapyAdvisor.com

Haymarket Media Inc., publisher of Monthly Prescribing Reference (MPR), MPR Hematology/Oncology Edition, and Oncology Nurse Advisor (ONA), is pleased to announce the launch of ChemotherapyAdvisor.com, offering oncologists and their support teams a unique clinical decision support tool.

23 Jan 2012

Study provides valuable information on which cancer patients might need help to quit smoking

A new analysis has found that a substantial number of lung and colorectal cancer patients continue to smoke after being diagnosed. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study provides valuable information on which cancer patients might need help to quit smoking.

23 Jan 2012

Sex declared safe for heart patients

A doctors’ group on Thursday suggested that sex may be safe for most heart patients. The American Heart Association added that having sex only slightly raises the chance for a heart attack. And that’s true for people with and without heart disease. Despite the higher risk for a heart patient to have a second attack, there’s no evidence that they have more sex-related heart attacks than people without cardiac disease. The updated advice was released online Thursday in the heart association journal, Circulation.

22 Jan 2012

Adding oxaliplatin to adjuvant 5FU improves survival of patients with stage III colon cancer

Stage III colon cancer patients in the general population who receive adjuvant treatment for the disease have an improved rate of survival when oxaliplatin is added to 5-fluorouracil (5FU), according to a study published Jan. 20 in the Journal of the National Cancer Institute.

21 Jan 2012

UHCMC now offers HITEC for women with gynecologic cancers

Patients with gynecologic cancer have new hope in a novel technology now offered at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center. A team of cancer specialists, led by Robert DeBernardo, MD, is among the first in the nation to launch a dedicated program using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat ovarian, endometrial and select other cancers.

21 Jan 2012